Table 4.

Convergent validity^a

Variable	PD‐CRS		Total PD‐CDR
	Subcortical	Cortical
Age, y	−0.54	−0.41	−0.54
Education, y	0.58	0.54	0.58
Disease duration, y	−0.27	−0.14	−0.24
Levodopa
Time on treatment, y	−0.21	−0.74	−0.18
Dose, mg/d	−0.31	−0.20	−0.29
SPES‐Scopa
Section 1	−0.48	−0.40	−0.47
Section 2	−0.50	−0.45	−0.49
Section 3	−0.22	−0.09	−0.19
Total	−0.47	−0.38	−0.45
Schwab & England	0.51	0.47	0.50
MMSE	0.73	0.71	0.76
HADS
Anxiety	−0.32	−0.28	−0.34
Depression	−0.36	−0.28	−0.35
PIMS	−0.34	−0.21	−0.33
SCOPA‐Psychosocial	−0.36	−0.32	−0.35
PPRS	−0.30	−0.35	−0.34
CISI‐PD	−0.59	−0.51	−0.59

^aData are Spearman rho values.

PD‐CRS, Parkinson's Disease Cognitive Rating Scale; SPES‐Scopa, Short Parkinson's Evaluation Scale‐Scales for Outcomes in Parkinson's Disease; MMSE, Mini‐Mental Status Examination; HADS, Hospital Anxiety and Depression Scale; PIMS, Parkinson's Impact Scale; SCOPA, Scales for Outcomes in Parkinson's Disease; PPRS, Parkinson's Psychosis Rating Scale; CISI‐PD, Clinical Impression of Severity Index for Parkinson's Disease.